Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Dyne Therapeutics to $27 from $29 and keeps an Overweight rating on the shares. The firm notes Dyne issued 17.15M shares at $17.50 raising gross proceeds of $300M, bringing pro forma cash to $458M excluding underwriters’ fees and Q4 2023 burn.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Dyne Therapeutics 17.15M share Spot Secondary priced at $17.50
- Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics announces $175M common stock offering